BCG is indicated for intravesical immunotherapy of non–muscle-invasive bladder cancer (NMIBC) with intermediate- or high-risk of recurrence and/or progression, including carcinoma in situ; see the tables on recurrence risk (Si apre in una nuova finestra) and progression risk (Si apre in una nuova finestra).
https://www.urology-textbook.com/bcg-intravesical.html (Si apre in una nuova finestra)
Data
17/11/2025
0 commenti
Vuoi essere la prima persona a commentare?
Abbonati a urology-textbook.com e avvia una conversazione.